In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US-EU Inspection Deal Hits Milestone As Batch Test Waiver Kicks In

Executive Summary

After 20 years in the making, the landmark GMP inspection MRA between the US and the EU is finally fully implemented. In addition, a batch test waiver has started to apply under the deal.

You may also be interested in...



IGBA Urges Action To Ensure Sustainability

A series of global policy recommendations has been set out by the International Generic and Biosimilar Medicines Association as part of efforts to ensure a sustainable industry environment and maintain patient access to off-patent drugs.

US And EU Look To Expand Inspection Agreement

Product pre-approval inspections, vaccines and plasma-derived products are on the discussion agenda as the US-EU mutual recognition agreement takes full effect.

Germany Joins EU-US Inspections MRA

There is now only one country left to join the agreement between the EU and the US on recognizing the findings of inspectorates in each other’s jurisdictions.

Topics

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel